Company accuses agency of reversal but hopes to settle on parameters of a new trial
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
The Food and Drug Administration has concluded that an experimental treatment for Huntington’s disease developed by UniQure was not providing benefit for patients based on existing clinical data, a senior FDA official told STAT, explaining the agency’s decision to block the company from submitting a marketing application.
Agency reviewers “are not convinced there’s any therapeutic benefit of the product,” the official said, speaking on condition of anonymity.
“If we felt there was any therapeutic benefit, we, of course, would approve it. But they’re not persuaded,” the official added.
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
To read the rest of this story subscribe to STAT+.
